newsfilter
← Latest News
GlobeNewswire·

MapLight Therapeutics Announces Pricing of Initial Public Offering

  • MapLight Therapeutics priced its initial public offering of 14,750,000 common stock shares at $17.00 per share.
  • Underwriters were granted a 30-day option to purchase up to an additional 2,212,500 shares at the initial offering price.
  • MapLight completed a concurrent private placement of 476,707 shares to affiliates of Goldman Sachs & Co. LLC, which is unregistered under the Securities Act of 1933.
  • Gross proceeds from the IPO & concurrent private placement are expected to be $258.9 million before deducting underwriting discounts, commissions, & offering expenses.
  • Shares are expected to begin trading on the Nasdaq Global Market on October 27, 2025, under the symbol "MPLT".
  • The offering & private placement are expected to close on October 28, 2025, subject to customary closing conditions, with the private placement contingent upon the successful closing of the IPO.
  • Morgan Stanley, Jefferies, Leerink Partners, & Stifel are acting as joint book-running managers for the offering.
  • The company is a clinical-stage biopharmaceutical firm focused on central nervous system disorders, with its lead candidate ML-007C-MA currently in Phase 2 trials for schizophrenia & Alzheimer's disease psychosis.